Literature DB >> 22967833

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

Steve N Caritis1, Shringi Sharma, Raman Venkataramanan, Gary D Hankins, Menachem Miodovnik, Mary F Hebert, Jason G Umans, Thomas Benedetti, Donald Mattison, Anne Zajicek, Dawn Fischer, Aimee Jackson.   

Abstract

OBJECTIVE: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. STUDY
DESIGN: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery.
RESULTS: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection.
CONCLUSION: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22967833      PMCID: PMC3586341          DOI: 10.1016/j.ajog.2012.08.015

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.

Authors: 
Journal:  Obstet Gynecol       Date:  2008-10       Impact factor: 7.661

2.  Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations.

Authors:  J Michaelis; H Michaelis; E Glück; S Koller
Journal:  Teratology       Date:  1983-02

3.  Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria.

Authors:  Valentina M Fokina; Olga L Zharikova; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Reprod Sci       Date:  2011-12-02       Impact factor: 3.060

4.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2011-03-22       Impact factor: 8.661

5.  Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy.

Authors:  T R Varma; J Morsman
Journal:  Int J Gynaecol Obstet       Date:  1982-02       Impact factor: 3.561

6.  Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.

Authors:  Shringi Sharma; Ewa C S Ellis; Kenneth Dorko; Shimin Zhang; Donald R Mattison; Steve N Caritis; Raman Venkataramanan; Stephen C Strom
Journal:  Drug Metab Dispos       Date:  2010-01-22       Impact factor: 3.922

7.  Effects of prenatally administered 17 alpha-hydroxyprogesterone caproate on adolescent males.

Authors:  P A Kester
Journal:  Arch Sex Behav       Date:  1984-10

8.  Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.

Authors:  Steve N Caritis; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Valerija Momirova; Catherine Y Spong; Jay D Iams; Ronald J Wapner; Michael Varner; Marshall Carpenter; Julie Lo; John Thorp; Brian M Mercer; Yoram Sorokin; Margaret Harper; Susan Ramin; Garland Anderson
Journal:  Obstet Gynecol       Date:  2009-02       Impact factor: 7.661

9.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth.

Authors:  Shringi Sharma; Junhai Ou; Stephen Strom; Don Mattison; Steve Caritis; Raman Venkataramanan
Journal:  Drug Metab Dispos       Date:  2008-06-23       Impact factor: 3.922

View more
  23 in total

Review 1.  Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.

Authors:  Jodie M Dodd; Rosalie M Grivell; Cecelia M OBrien; Therese Dowswell; Andrea R Deussen
Journal:  Cochrane Database Syst Rev       Date:  2017-10-31

Review 2.  What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.

Authors:  Steve N Caritis; Maisa N Feghali; William A Grobman; Dwight J Rouse
Journal:  Semin Perinatol       Date:  2016-04-19       Impact factor: 3.300

Review 3.  Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2014-09-23       Impact factor: 3.300

4.  Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.

Authors:  Steve N Caritis; Raman Venkataramanan; Elizabeth Thom; Margaret Harper; Mark A Klebanoff; Yoram Sorokin; John M Thorp; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; William A Grobman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan Ramin
Journal:  Am J Obstet Gynecol       Date:  2013-10-07       Impact factor: 8.661

5.  Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases.

Authors:  Steve N Caritis; Gary Hankins; Mary Hebert; David M Haas; Mahmoud Ahmed; Hyagriv Simhan; Laura A Haneline; John Harris; Justine Chang; Alyssa Stephenson Famy; Patrick Yorio; Zhaoxia Ren; Mary E D'Alton; Raman Venkataramanan
Journal:  Am J Perinatol       Date:  2017-11-15       Impact factor: 1.862

6.  The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.

Authors:  Martha L Bustos; Steve N Caritis; Kathleen A Jablonski; Uma M Reddy; Yoram Sorokin; Tracy Manuck; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; Alan M Peaceman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan M Ramin
Journal:  Am J Obstet Gynecol       Date:  2017-05-15       Impact factor: 8.661

7.  Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.

Authors:  Steve N Caritis; Yang Zhao; Joseph Bettinger; Raman Venkataramanan
Journal:  Am J Obstet Gynecol       Date:  2013-02-20       Impact factor: 8.661

8.  Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.

Authors:  Shringi Sharma; Steve Caritis; Gary Hankins; Menachem Miodovnik; Mary F Hebert; Don Mattison; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2016-07-13       Impact factor: 4.335

9.  Developmental exposure to 17α-hydroxyprogesterone caproate impairs adult delayed reinforcement and reversal learning in male and female rats.

Authors:  Rebecka O Serpa; Christine K Wagner; Ruth I Wood
Journal:  J Neuroendocrinol       Date:  2020-06-02       Impact factor: 3.627

Review 10.  Basic obstetric pharmacology.

Authors:  Yang Zhao; Mary F Hebert; Raman Venkataramanan
Journal:  Semin Perinatol       Date:  2014-10-01       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.